Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.53 |
| ▸ | RAD52 | P43351 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | ANPEP | P15144 | 1/20 | 0.42 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5896953 | 0.86 | CXCR4 (0.50) | HSD17B10RAD52SMN1; SMN2POLBCXCR4 | |
| SCHEMBL845511 | 0.80 | HSD17B10 (0.57) | HSD17B10RAD52SMN1; SMN2POLBCXCR4 | |
| SCHEMBL29860764 | 0.78 | HSD17B10 (0.55) | HSD17B10RAD52SMN1; SMN2POLBCXCR4 | |
| SCHEMBL2076864 | 0.77 | — | — | |
| SCHEMBL681608 | 0.76 | CARM1 (0.62) | HSD17B10RAD52SMN1; SMN2POLBCXCR4 | |
| SCHEMBL21846921 | 0.76 | HSD17B10 (0.53) | HSD17B10RAD52SMN1; SMN2POLBCXCR4 | |
| SCHEMBL14500286 | 0.76 | HSD17B10 (0.53) | HSD17B10RAD52SMN1; SMN2POLBCXCR4 | |
| SCHEMBL237512 | 0.76 | POLB (0.59) | HSD17B10RAD52SMN1; SMN2POLBCXCR4 | |
| SCHEMBL2077311 | 0.75 | CARM1 (0.54) | POLBMEN1KMT2AALDH1A1L3MBTL1 | |
| SCHEMBL6051874 | 0.74 | ACE2 (0.52) | HSD17B10RAD52SMN1; SMN2POLBCXCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1490367-B1 | IMIDAZOPYRIDINE DERIVATIVES AS KINASE INHIBITORS | GLAXO GROUP LTD (GB) | 2008-07-23 | — | — | EP | claimed |
| US-7060700-B2 | Amide derivatives useful as inhibitors of the production of cytokines | ASTRAZENECA AB (SE) | 2006-06-13 | — | — | US | claimed |
| US-20050245551-A1 | Amide derivatives | ASTRAZENECA AB | 2005-11-03 | — | — | US | claimed |
| EP-1163212-B1 | AMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2005-08-31 | — | — | EP | claimed |
| US-6794380-B2 | ANTIINFLAMMATORY AGENTS; AUTOIMMUNE DISEASE; ANTIALLERGENS | ASTRAZENECA AB (SE) | 2004-09-21 | — | — | US | claimed |
| EP-1163237-B1 | AMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2004-05-06 | — | — | EP | claimed |
| EP-1115707-B1 | BENZAMIDE DERIVATIVES AND THER USE AS CYTOKINE INHIBITORS | ASTRAZENECA AB (SE) | 2003-11-12 | — | — | EP | claimed |
| US-20030186966-A1 | Amide derivatives | ASTRAZENECA AB | 2003-10-02 | — | — | US | claimed |
| US-20030105142-A1 | Amide derivatives useful as inhibitors of the production of cytokines | ASTRAZENECA AB | 2003-06-05 | — | — | US | claimed |
| US-6548514-B1 | Inhibitors of p38 kinase/cytokine suppressive binding protein (CSBP)/reactivating kinase (RK); 1-((pyridyl)aminocarbonyl)-3-((hetero)arylaminocarbonyl)benzene derivatives; treating cytokine related diseases and disorders | ASTRAZENECA AB (SE) | 2003-04-15 | — | — | US | claimed |
| US-6455520-B1 | TUMOR NECROSIS FACTOR AND INTERLEUKIN INHIBITORS; ANTIINFLAMMATORY AGENTS, ANTIALLERGENS; BONE DISORDERS | ASTRA ZENECA AB (SE) | 2002-09-24 | — | — | US | claimed |
| US-6432949-B1 | Amide derivatives useful as inhibitors of the production of cytokines | ASTRAZENECA AB (SE) | 2002-08-13 | — | — | US | claimed |
| EP-1163212-A1 | AMIDE DERIVATIVES | AstraZeneca AB (SE) | 2001-12-19 | — | — | EP | claimed |
| EP-1163237-A1 | AMIDE DERIVATIVES | AstraZeneca AB (SE) | 2001-12-19 | — | — | EP | claimed |
| EP-1115707-A1 | BENZAMIDE DERIVATIVES AND THER USE AS CYTOKINE INHIBITORS | AstraZeneca AB (SE) | 2001-07-18 | — | — | EP | claimed |
| EP-1102750-A1 | AMIDE DERIVATIVES USEFUL AS INHIBITORS OF THE PRODUCTION OF CYTOKINES | AstraZeneca AB (SE) | 2001-05-30 | — | — | EP | claimed |
| WO-2000055120-A1 | AMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2000-09-21 | — | — | WO | claimed |
| WO-2000055153-A1 | AMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2000-09-21 | — | — | WO | claimed |
| WO-2000018738-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS | ASTRAZENECA AB (SE) | 2000-04-06 | — | — | WO | claimed |
| WO-2000007991-A1 | AMIDE DERIVATIVES USEFUL AS INHIBITORS OF THE PRODUCTION OF CYTOKINES | ASTRAZENECA AB (SE) | 2000-02-17 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245551-A1 | Amide derivatives | IL6, IL6ST, IL1B | HSD17B10 455/4885RAD52 4518/4885SMN1; SMN2 2166/4885 |
| US-20030105142-A1 | Amide derivatives useful as inhibitors of the production of cytokines | IL6, IL6ST, IL2 | HSD17B10 525/4885RAD52 4756/4885SMN1; SMN2 3728/4885 |
| US-20030186966-A1 | Amide derivatives | IL6, IL6ST, IFNG | HSD17B10 929/4885RAD52 4747/4885SMN1; SMN2 2253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.